Monashee Investment Management LLC bought a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 100,000 shares of the company’s stock, valued at approximately $896,000. Monashee Investment Management LLC owned 0.06% of Vir Biotechnology as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also modified their holdings of the company. Raymond James Financial Inc. bought a new position in Vir Biotechnology in the 2nd quarter valued at about $35,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Vir Biotechnology by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock worth $41,000 after acquiring an additional 1,390 shares during the last quarter. UMB Bank n.a. boosted its holdings in shares of Vir Biotechnology by 1,418.7% during the fourth quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock worth $43,000 after acquiring an additional 6,597 shares during the period. CWM LLC grew its position in shares of Vir Biotechnology by 23.0% in the fourth quarter. CWM LLC now owns 8,804 shares of the company’s stock valued at $53,000 after purchasing an additional 1,646 shares during the last quarter. Finally, Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Vir Biotechnology in the fourth quarter valued at approximately $60,000. Institutional investors own 65.32% of the company’s stock.
Vir Biotechnology Trading Down 0.7%
NASDAQ VIR opened at $9.35 on Thursday. The company has a market cap of $1.58 billion, a price-to-earnings ratio of -2.99 and a beta of 1.62. The company has a 50 day moving average of $9.34 and a 200-day moving average of $8.82. Vir Biotechnology, Inc. has a 1-year low of $4.16 and a 1-year high of $11.66.
Analyst Upgrades and Downgrades
Several analysts recently weighed in on the company. Leerink Partners lifted their price target on Vir Biotechnology from $20.00 to $21.00 and gave the stock an “outperform” rating in a report on Wednesday, June 3rd. Morgan Stanley upped their price objective on Vir Biotechnology from $23.00 to $27.00 and gave the company an “overweight” rating in a report on Thursday, June 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vir Biotechnology in a report on Wednesday, July 8th. Finally, Wall Street Zen cut Vir Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $20.88.
View Our Latest Research Report on VIR
Insider Buying and Selling at Vir Biotechnology
In other Vir Biotechnology news, Director Vicki L. Sato sold 22,000 shares of the stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $10.05, for a total transaction of $221,100.00. Following the sale, the director directly owned 1,078,391 shares in the company, valued at $10,837,829.55. This represents a 2.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Janet Napolitano sold 3,200 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $9.45, for a total transaction of $30,240.00. Following the completion of the transaction, the director directly owned 21,216 shares in the company, valued at approximately $200,491.20. This represents a 13.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 25,579 shares of company stock worth $254,922. 2.90% of the stock is currently owned by insiders.
Vir Biotechnology Company Profile
Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.
The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.
Read More
- Five stocks we like better than Vir Biotechnology
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Want to see what other hedge funds are holding VIR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report).
Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
